Core Viewpoint - Xintiandi (301277.SZ) has received approval from the National Medical Products Administration for the raw material drug Ferrous Fumarate, which is used for the prevention and treatment of iron deficiency anemia [1] Group 1 - The approval includes the issuance of the "Chemical Raw Material Drug Marketing Application Approval Notice" for Ferrous Fumarate [1] - Ferrous Fumarate is an iron supplement that improves hemoglobin synthesis and alleviates symptoms related to anemia [1]

Core Viewpoint - The company, New World (301277), has received approval from the National Medical Products Administration for the raw material drug Ferrous Fumarate, which is used to prevent and treat iron deficiency anemia [1] Group 1 - The approval includes the issuance of the "Chemical Raw Material Drug Listing Application Approval Notice" for Ferrous Fumarate [1] - Ferrous Fumarate is an iron supplement that improves hemoglobin synthesis and alleviates symptoms related to anemia [1]

证券代码：301277 证券简称：新天地 公告编号：2025-053 新天地药业股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 2025年12月08日，新天地药业股份有限公司（以下简称"公司"）收到国 家药品监督管理局核准签发的富马酸亚铁原料药《化学原料药上市申请批准通 知书》，现将相关情况公告如下： | 化学原料药名称 | 通用名称：富马酸亚铁 英文名/拉丁名：Ferrous | | --- | --- | | | Fumarate | | 通知书编号 | 2025YS01084 | | 登记号 | Y20240000827 | | 有效期 | 18个月 | | 包装规格 | 25kg/桶 | | 申请事项 | 境内生产化学原料药上市申请 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册。质量标准、标签及生 | | | 产工艺照所附执行。 | | 生产企业 | 名称：新天地药业股份有限公司 | | | 地址：长葛市魏武路南段东侧 | | ...

Core Perspective - Rolex is launching a new watch series, the Oyster Perpetual Land-Dweller, in Spring 2025, marking a significant expansion beyond its traditional aviation and diving segments, focusing on a harmonious coexistence with the world rather than extreme environments [1] Group 1: Design and Aesthetics - The Land-Dweller series embodies the principle of "heritage and future," integrating advanced technology and aesthetic design through a comprehensive R&D process [3] - The watch features a unique "high-tech matte" finish on Oyster steel and precious metal models, creating a visual contrast with polished edges, resulting in a layered light effect [3] - The new "Flat Jubilee" bracelet seamlessly connects to the Oyster case, showcasing top-tier craftsmanship and visual fluidity [5] - The exclusive "honeycomb pattern" dial symbolizes stability and efficiency, reflecting the wearer's journey of steady progress [5][7] Group 2: Movement and Technology - The new 7135 movement operates at a high frequency of 5 Hz, allowing for time display accuracy to 1/10 of a second, while maintaining approximately 66 hours of power reserve [9] - Rolex has developed a patented "dynamic pulse escapement system" to enhance energy transfer efficiency, addressing challenges associated with high-frequency movements [9] - The movement's stability and durability are further ensured by upgraded components, including a ceramic balance wheel and optimized silicon hairspring [9] Group 3: Material and Functionality - The watch features a combination of Oyster steel and 18K white gold, balancing durability with luxury, suitable for various occasions [13] - The "ChromaLight" luminescent material enhances visibility in low light, providing a unique visual characteristic for the series [13] - Design elements such as the calendar magnifier and the widened triangular bezel reflect both functional needs and brand heritage, positioning the watch as a versatile daily wear piece [14] Group 4: Brand Messaging and Identity - The Land-Dweller series aims to convey a message of grounded ambition and future-building, resonating with the lifestyles of its wearers, exemplified by ambassadors like Roger Federer [16][18] - The watch symbolizes the philosophy of achieving greatness through dedication to the present and a clear vision for the future [18]

Core Viewpoint - The company announced the conclusion of two fundraising investment projects and plans to use the remaining funds to permanently supplement its working capital and cancel the fundraising account [1] Group 1: Investment Projects - The company will hold the sixth board meeting and the sixth supervisory board meeting on December 6, 2025, to review the conclusion of the fundraising investment projects [1] - The projects include the "Annual Production of 120 Tons of Raw Materials Construction Project" and the "Intelligent Specialty Raw Material Pharmaceutical Supporting Industrial Chain Project," both of which have reached the predetermined usable state [1] Group 2: Fund Management - The company intends to use the surplus fundraising funds (including interest income and cash management returns, with the specific amount based on the balance of the fundraising account on the transfer date) to permanently supplement its working capital [1] - The proposal to conclude the projects and manage the surplus funds will be submitted for shareholder meeting approval [1]

Core Viewpoint - The company has announced the completion of two fundraising investment projects and plans to permanently supplement its working capital with the remaining funds, which will enhance operational efficiency and benefit all shareholders [1][2]. Group 1: Project Completion - The company will hold its sixth board and supervisory meeting on December 6, 2025, to approve the completion of the "Annual Production of 120 Tons of Raw Materials Project" and the "Intelligent Specialty Raw Material Pharmaceutical Supporting Industry Chain Project" [1]. - The "Annual Production of 120 Tons of Raw Materials Project" had a planned investment of 264 million yuan, with 136 million yuan already invested [1]. - The "Intelligent Specialty Raw Material Pharmaceutical Supporting Industry Chain Project" had a planned investment of 100 million yuan, with 36.759 million yuan already invested [1]. Group 2: Financial Implications - The remaining funds from the completed projects, including interest income and cash management returns, will be used to permanently supplement the company's working capital [1][2]. - This move is expected to meet the company's daily operational needs and improve overall operational efficiency [2].

Group 1 - The company Xintiandi (SZ 301277) announced that its sixth board meeting will be held on December 6, 2025, to review the proposal for amending the "Board Secretary Work Guidelines" [1] - For the first half of 2025, Xintiandi's revenue composition shows that pharmaceutical intermediates account for 98.23%, while other businesses make up 1.77% [1] - As of the report date, Xintiandi's market capitalization is 4.8 billion yuan [1] Group 2 - A report highlighted the first case of pregabalin abuse leading to addiction in China, revealing vulnerabilities in online platforms that allow drug purchases without medical records [1]

证券代码：301277 证券简称：新天地 公告编号：2025-051 新天地药业股份有限公司 关于募集资金投资项目结项并将节余募集资金永久补充流动 资金及注销募集资金专户的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 新天地药业股份有限公司（以下简称"公司"）于2025年12月06日召开第 六届董事会第九次会议和第六届监事会第九次会议，审议通过《关于募集资金 投资项目结项并将节余募集资金永久补充流动资金及注销募集资金专户的议 案》。公司首次公开发行股票募集资金投资项目"年产120吨原料药建设项目" 和使用首次公开发行股票超募资金投资建设的"智能化特色原料药配套产业链 项目"已达到预定可使用状态，公司拟将上述项目进行结项，并将节余募集资 金（含利息收入及现金管理收益等，具体金额以资金转出当日募集资金专户余 额为准）用于永久补充流动资金并注销募集资金专户。该议案尚需提交股东会 审议，现将有关事项公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意河南新天地药业股份有限公司首次公 开发行股票注册的批复》（证监许可[2022]1911号）核准 ...

证券代码：301277 证券简称：新天地 公告编号：2025-050 新天地药业股份有限公司 关于变更注册资本、调整公司治理结构、修订《公司章程》 及制定、修订、废止公司部分治理制度的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 新天地药业股份有限公司（以下简称"公司"）于2025年12月6日召开第 六届董事会第九次会议，审议通过了《关于变更公司注册资本、调整公司治 理结构、修订<公司章程>并办理工商变更登记的议案》《关于制定、修订公 司部分治理制度的议案》，同日召开的第六届监事会第九次会议审议通过了 《关于变更公司注册资本、调整公司治理结构、修订<公司章程>并办理工商 变更登记的议案》《关于废止<监事会议事规则>的议案》，现将具体情况公 告如下： 一、变更公司注册资本情况 公司2024年年度权益分派方案已实施完成，具体内容为：以2024年12月 31日总股本280,056,000股为基数，向全体股东每10股派发现金红利4.00元（含 税），合计派发现金红利112,022,400元（含税）；以资本公积金转增股本， 每 10 股 转 增 4 股 ， 合 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要提示： 新天地药业股份有限公司（以下简称"公司"）根据 2025 年 12 月 6 日召 开的第六届董事会第九次会议决议，定于 2025 年 12 月 24 日下午 14:30 在公 司召开 2025 年第三次临时股东会。现将召开本次会议有关事宜通知如下： 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司 章程》的有关规定。 证券代码：301277 证券简称：新天地 公告编号：2025-052 新天地药业股份有限公司 关于召开 2025 年第三次临时股东会的通知 4、会议时间： （1）现场会议时间：2025 年 12 月 24 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 24 日 9:15-9:25，9:30-11 ...